Miller, Michael

A Deficiency of Nutrition Education and Practice in Cardiology

Devries, S., Agatston, A., Aggarwal, M., Aspry, K. E., Esselstyn, C. B., Kris-Etherton, P., Miller, M., O'Keefe, J. H., Ros, E., Rzeszut, A. K., et al. (2017) · The American Journal of Medicine

Dietetics, Nutrition, and EducationInnovations in Medical Education

Cited by 126

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial

Bhatt, D. L., Bays, H. E., Miller, M., Cain, J. E., Wasilewska, K., Andrawis, N. S., Parli, T., Feng, S., Sterling, L., Tseng, L., et al. (2023) · Nature Medicine

Lipid metabolism and disordersFibroblast Growth Factor Research

Cited by 121

Relative Atherogenicity and Predictive Value of Non–High-Density Lipoprotein Cholesterol for Coronary Heart Disease

Miller, M., Ginsberg, H. N., & Schaefer, E. J. (2008) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 102

Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles

Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Jiao, L., Tardif, J.-C., Gregson, J., Pocock, S. J., & Ballantyne, C. M. (2019) · Journal of the American College of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 97

Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study

Bartlett, J., Predazzi, I. M., Williams, S. M., Bush, W. S., Kim, Y., Havas, S., Toth, P. P., Fazio, S., & Miller, M. (2016) · Circulation: Cardiovascular Quality and Outcomes

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 96

APOC3 Promoter Polymorphisms C-482T and T-455C Are Associated with the Metabolic Syndrome

Miller, M., Rhyne, J., Chen, H., Beach, V., Ericson, R., Luthra, K., Dwivedi, M., & Misra, A. (2007) · Archives of Medical Research

Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 89

Reduced hippocampal volume in alcohol and substance naïve Vietnam combat veterans with posttraumatic stress disorder

Hedges, D. W., Allen, S., Tate, D. F., Thatcher, G. W., Miller, M. J., Rice, S. A., Cleavinger, H. B., Sood, S., & Bigler, E. D. (2003) · Cognitive and Behavioral Neurology

Posttraumatic Stress Disorder ResearchTraumatic Brain Injury Research

Cited by 80

Tailoring cannabis dependence treatment for a diverse population

Steinberg, K. L., Roffman, R. A., Carroll, K. M., Kabela, E., Kadden, R., Miller, M., Duresky, D., & The Marijuana Treatment Project Research Group (2002) · Addiction

Substance Abuse Treatment and OutcomesCannabis and Cannabinoid Research

Cited by 64

Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction

Gaba, P., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American College of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 61

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses

Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2021) · Circulation

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 57

Poly is more effective than monounsaturated fat for dietary management in the metabolic syndrome: The muffin study

Miller, M., Sorkin, J. D., Mastella, L., Sutherland, A., Rhyne, J., Donnelly, P., Simpson, K., & Goldberg, A. P. (2016) · Journal of clinical lipidology

Fatty Acid Research and HealthNutritional Studies and Diet

Cited by 41

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia

Rosenson, R. S., Jacobson, T. A., Preiss, D., Djedjos, C. S., Dent, R., Bridges, I., & Miller, M. (2016) · Cardiovascular Drugs and Therapy

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 36

Cardiovascular benefits of icosapent ethyl in patients with and without atrial fibrillation in REDUCE-IT

Olshansky, B., Bhatt, D. L., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., et al. (2023) · Journal of the American Heart Association

Fatty Acid Research and HealthAtrial Fibrillation Management and Outcomes

Cited by 29

Optimizing Non-Pharmacologic Management of Hypertriglyceridemia

Byrne, A., Makadia, S., Sutherland, A., & Miller, M. (2017) · Archives of Medical Research

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 27

Reductions in Anxiety and Depression Symptoms in Youth Receiving Substance Use Treatment: Reductions in Comorbidity in Adolescent Substance Users

Horigian, V. E., Weems, C. F., Robbins, M. S., Feaster, D. J., Ucha, J., Miller, M., & Werstlein, R. (2013) · The American Journal on Addictions

Substance Abuse Treatment and OutcomesChild and Adolescent Psychosocial and Emotional Development

Cited by 21

Incorporation of oleic acid and eicosapentaenoic acid into glycerolipids of cultured normal human fibroblasts

Miller, M., Motevalli, M., Westphal, D., & Kwiterovich, P. O. (1993) · Lipids

Lipid metabolism and biosynthesisFatty Acid Research and Health

Cited by 17

Prediction of outcome of bright light treatment in patients with seasonal affective disorder: Discarding the early response, confirming a higher atypical balance, and uncovering a higher body mass index at baseline as predictors of endpoint outcome

Dimitrova, T. D., Reeves, G. M., Snitker, S., Lapidus, M., Sleemi, A. R., Balis, T. G., Manalai, P., Tariq, M. M., Cabassa, J. A., Karim, N. N., et al. (2017) · Journal of Affective Disorders

Circadian rhythm and melatoninTreatment of Major Depression

Cited by 16

COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN US REDUCE-IT PATIENTS

Weintraub, W. S., Bhatt, D., Zhang, Z., Zhang, C., Sarahfaye, D., Boden, W. E., Steg, P. G., Miller, M., Brinton, E., King, J., et al. (2020) · Journal of the American College of Cardiology

Fatty Acid Research and HealthHealth Systems, Economic Evaluations, Quality of Life

Cited by 13

Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn

Miller, M., Bhatt, D. L., Brinton, E. A., Jacobson, T. A., Steg, P. G., Pineda, A. L., Ketchum, S. B., Doyle, R. T., Tardif, J.-C., & Ballantyne, C. M. (2023) · European Heart Journal Open

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 11

Reply

Bhatt, D. L., Steg, P. G., Miller, M., Juliano, R. A., & Ballantyne, C. M. (2019) · Journal of the American College of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 11

Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT

Szarek, M., Bhatt, D., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Tardif, J. C., Ballantyne, C. M., Ketchum, S. B., Pineda, A. L., et al. (2023) · European Heart Journal

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 9

Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease

Miller, M. (2024) · Current Opinion in Cardiology

Lipoproteins and Cardiovascular HealthFatty Acid Research and Health

Cited by 7

Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM

Miller, M., Bhatt, D. L., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Pineda, A. L., Tardif, J.-C., & Ballantyne, C. M. (2026) · American Journal of Preventive Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 0